CLRB Earnings Prediction
The chart below shows how CLRB performed 10 days before and after its earnings report, based on data from the past quarters. Typically, CLRB sees a +4.41% change in stock price 10 days leading up to the earnings, and a +0.48% change 10 days following the report. On the earnings day itself, the stock moves by -0.50%. This data can give you a slight idea of what to expect for the next quarter's release.
CLRB Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.37
-76.13%
1133.33%
No Data Available
CLRB Earnings Analysis
Cellectar Biosciences INC NEW Corporation (CLRB.O) Earnings Conference Call
Positive
CLOVER WaM Study Results: The CLOVER WaM study reported a major response rate of 56.4%, with an overall response rate of 80% and a clinical benefit rate of 98.2%.
Cash Position Improvement: The company ended the quarter with cash and cash equivalents of $34.3 million, compared to $9.6 million as of December 31, 2023.
Potential Funds from Warrants: Funds raised in July 2024 from investor exercises of Tranche B warrants and purchase of new warrants have the potential to raise up to an additional $73.3 million.
Manufacturing Capacity Expansion: The company has made substantial progress in securing its second iopofosine I-131 fit and finish manufacturing source, providing additional production capacity and product supply redundancy at launch.
Clinical Development Collaboration: The collaboration with the City of Hope Cancer Center focuses on the clinical development of iopofosine I-131 in mycosis fungoides, demonstrating the company's commitment to advancing its promising clinical pipeline.
Negative
Net Loss Comparison: Net loss for the period ended September 30, 2024 was $14.7 million or $0.37 per basic share, compared with $17.5 million or $1.55 per basic share during the same period in 2023.
R&D Expense Comparison: Research and development expenses for the three months ended September 30, 2024 were approximately $5.5 million, compared to approximately $7.0 million for the three months ended September 30, 2023.
Administrative Expense Increase: General and administrative expenses for the three months ended September 30, 2024 were $7.8 million, compared to $2.4 million for the same period in 2023.
R&D Cost Dynamics: The overall increase in R&D was primarily a result of decreased clinical study costs driven by the conclusion of patient enrollment and our WM pivotal study having occurred earlier this year, partially offset by increased activity in our ongoing pediatric trial and an increase in personnel costs.
Warrant Tranche Funding: The three warrant tranches issued in July provide additional funding based upon their respective expiration dates, which occur with the first tranche of approximately $17.0 million after we received a PDUFA date from the FDA.
CLRB FAQs
How does CLRB typically perform around its earnings report dates?
Is Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
CLRB Earning Call Sentiment
Cellectar Biosciences, Inc. (CLRB) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
CLRB.O
0.7%Positive
The earnings call presents mixed signals. While there are positive elements like a reduced net loss and potential funding from warrants, there are also concerns such as regulatory delays and financial reporting issues. The Q&A section highlights uncertainties regarding FDA studies and cash runway, which could impact investor sentiment. Without a clear market cap, it's difficult to assess the stock's volatility, but the overall sentiment is neutral, considering both positive and negative factors.
